After GBS outbreak in Madhya Pradesh’s Neemuch district, doctors explain how the immunological disorder presents in children, ...
At least two people died after a Guillain-Barré Syndrome outbreak in Madhya Pradesh's Neemuch district. So far 14 patients ...
Two persons have died after an outbreak of Guillain-Barré Syndrome, an immunological nerve disorder, in Madhya Pradesh’s ...
Real-world evidence study shows ANX005 improves muscle strength and functional outcomes in Guillain-Barré Syndrome compared to current treatments. Potential regulatory concerns may arise if the FDA ...
BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...
Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long-term ...
GBS is a disease in which a patient’s immune system mistakenly starts attacking the peripheral nervous system. The disease is ...
State government includes costly GBS therapy in Ayushman Bharat–Arogya Karnataka scheme, offering financial support to affected patients.
KYOTO, Japan — Eculizumab (Soliris, Alexion Pharmaceuticals) is safe for the treatment of patients with severe Guillain-Barré syndrome (GBS), a new phase 2 study shows. However, although more patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results